Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to "Hold" at Zacks Research

Key Points

• Theravance Biopharma's stock rating was downgraded from "strong-buy" to "hold" by Zacks Research in a recent analysis.
• The stock has shown volatility, opening at $13.87, with a 52-week low of $7.88 and high of $14.55, and currently has a market capitalization of approximately $698.49 million.
• Institutional investors control 99.10% of Theravance Biopharma's shares, indicating strong confidence in the company's long-term prospects despite the recent rating changes.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was downgraded by Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts also recently commented on the stock. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. B. Riley started coverage on shares of Theravance Biopharma in a research note on Friday, September 12th. They issued a "buy" rating and a $28.00 price objective for the company. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research note on Tuesday, June 17th. Finally, BTIG Research increased their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $23.00.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock traded down $0.59 on Monday, reaching $13.88. 465,356 shares of the stock were exchanged, compared to its average volume of 508,645. The firm's 50 day moving average is $12.67 and its 200-day moving average is $10.77. Theravance Biopharma has a one year low of $7.88 and a one year high of $14.55. The firm has a market cap of $699.00 million, a PE ratio of 57.83 and a beta of 0.05.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares of the company's stock, valued at $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 3,281 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 781 shares during the period. AQR Capital Management LLC bought a new position in shares of Theravance Biopharma in the 1st quarter worth approximately $101,000. R Squared Ltd lifted its stake in shares of Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 10,822 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Theravance Biopharma in the 4th quarter worth approximately $119,000. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.